FGEN FibroGen Inc.

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation

The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call . To access the call by phone, please , and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the  page on FibroGen’s website.

About FibroGen  

FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit .

For Investor Inquiries:

David DeLucia, CFA

Senior Vice President and Chief Financial Officer

   



EN
03/03/2025

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial resul...

16h / 11m 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Appro...

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million  Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure Company’s cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer ...

February 20, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Appoints David DeLucia as Chief Financial Officer SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and ...

December 16, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen Reports Third Quarter 2024 Financial Results Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full ...

November 12, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: To access the call, participants should dial the applicable telephone num...

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch